Ultragenyx Pharmaceutical Inc
RARE
NASDAQ
Biotechnology
$26.49
USD
+0.11 (+0.42%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.60B
Volume 1.2M
Revenue
$717.21M
TTM
+17.5%
YoY
Gross Margin
83%
TTM
-2.5%
YoY
Net Income
$-585.97M
TTM
-10.0%
YoY
Operating Cash Flow
$-485.25M
TTM
-15.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 167.0 | 159.9 | 207.3 | 136.0 | 214.0 |
YoY Growth | +13.6% | +14.7% | +25.9% | -2.2% | +28.1% |
Cost of Revenue | 23.0 | 28.0 | 29.3 | 30.0 | 34.0 |
Gross Profit | 144.0 | 131.9 | 177.9 | 106.0 | 180.0 |
Selling, General & Administrative | 87.0 | 86.6 | 87.9 | 88.0 | 88.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 252.0 | 302.8 | 291.2 | 275.0 | 255.0 |
Operating Income | -108.0 | -170.9 | -113.3 | -169.0 | -75.0 |
EBITDA | -99.0 | -162.3 | -104.5 | -161.0 | -67.0 |
Other Income / Expense | 2.0 | -0.4 | -1.4 | 0.0 | 1.0 |
Total Other Income / Expense | -6.0 | -8.7 | -14.4 | -15.0 | -16.0 |
Income Before Income Taxes | -114.0 | -179.5 | -127.7 | -184.0 | -91.0 |
Income Taxes | 1.0 | 0.9 | 0.9 | 1.0 | 1.0 |
Net Income | -115.0 | -180.4 | -128.6 | -185.0 | -92.0 |
Consolidated Net Income / Loss | -115.0 | -180.4 | -128.6 | -185.0 | -92.0 |
Net Income Attributable to Common Shareholders | -115.0 | -180.4 | -128.6 | -185.0 | -92.0 |
Basic EPS | -$1.17 | -$1.81 | -$1.29 | -$1.84 | -$0.90 |
Diluted EPS | -$1.17 | -$1.81 | -$1.29 | -$1.84 | -$0.90 |
Basic Shares Outstanding | 98.5M | 99.8M | 99.8M | 100.6M | 101.9M |
Diluted Shares Outstanding | 98.5M | 99.8M | 99.8M | 100.6M | 101.9M |